Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on May 9, 2013, covering events occurring on May 8, 2013. The filing primarily addresses Regulation FD disclosure regarding a scheduled media appearance by the principal investigator of the Company's Phase II clinical trial for NSI-566, a treatment for amyotrophic lateral sclerosis (ALS).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on the announcement of a media event and the formal designation of social media channels for material disclosures.
Guidance, Outlook, and Management Commentary
- Media Appearance: Dr. Eva Feldman, principal investigator of the Phase II trial for NSI-566, is scheduled to appear on Sirius XM's Doctor Radio on May 9, 2013.
- Management Commentary: CEO Richard Garr is anticipated to provide commentary via the Company's social media channels.
- Disclosure Channels: The Company formally announced it will use specific social media platforms (Twitter, Facebook, Company Blog, Google+, LinkedIn) to disclose material financial information and comply with Regulation FD.
- Risks and Contingencies: The filing includes standard disclaimers stating that the information is not "filed" for purposes of Section 18 of the Exchange Act and is not an admission of materiality solely to satisfy Regulation FD.
Key Facts for Investor Verification
- Verify the content of the press release attached as Exhibit 99.01 for details on the Phase II trial status.
- Monitor the listed social media channels (Twitter, Facebook, Blog, Google+, LinkedIn) for future material disclosures.
- Confirm the date and time of the Sirius XM broadcast (May 9, 10-11am EDT) to access the principal investigator's comments.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.